Sidoti Csr Research Analysts Reduce Earnings Estimates for Balchem Co. (NASDAQ:BCPC)

Balchem Co. (NASDAQ:BCPC) – Investment analysts at Sidoti Csr cut their Q2 2024 earnings per share (EPS) estimates for Balchem in a research note issued on Tuesday, July 9th. Sidoti Csr analyst K. May now expects that the basic materials company will post earnings of $0.99 per share for the quarter, down from their previous forecast of $1.06. The consensus estimate for Balchem’s current full-year earnings is $3.88 per share. Sidoti Csr also issued estimates for Balchem’s Q3 2024 earnings at $1.05 EPS, Q4 2024 earnings at $1.05 EPS, FY2024 earnings at $4.06 EPS, Q1 2025 earnings at $1.14 EPS, Q2 2025 earnings at $1.12 EPS, Q3 2025 earnings at $1.17 EPS, Q4 2025 earnings at $1.17 EPS and FY2025 earnings at $4.57 EPS.

Balchem (NASDAQ:BCPC) last released its quarterly earnings results on Friday, May 3rd. The basic materials company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). The firm had revenue of $239.66 million for the quarter, compared to analyst estimates of $234.12 million. Balchem had a return on equity of 11.03% and a net margin of 12.35%.

A number of other brokerages also recently commented on BCPC. HC Wainwright upped their price objective on shares of Balchem from $167.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, May 6th. StockNews.com raised shares of Balchem from a “hold” rating to a “buy” rating in a report on Friday, May 10th.

Balchem Stock Performance

NASDAQ BCPC opened at $166.08 on Thursday. The business’s 50-day moving average price is $154.86 and its 200 day moving average price is $150.27. The company has a quick ratio of 1.72, a current ratio of 2.61 and a debt-to-equity ratio of 0.30. The firm has a market cap of $5.38 billion, a P/E ratio of 46.92, a P/E/G ratio of 5.24 and a beta of 0.68. Balchem has a 52-week low of $110.74 and a 52-week high of $168.04.

Institutional Investors Weigh In On Balchem

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in shares of Balchem by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 3,791,512 shares of the basic materials company’s stock worth $563,987,000 after acquiring an additional 30,868 shares during the last quarter. APG Asset Management US Inc. purchased a new position in Balchem in the 4th quarter valued at about $39,164,000. Congress Asset Management Co. MA boosted its stake in shares of Balchem by 7.7% during the 1st quarter. Congress Asset Management Co. MA now owns 258,116 shares of the basic materials company’s stock worth $39,995,000 after purchasing an additional 18,459 shares during the last quarter. Heritage Wealth Management LLC purchased a new stake in shares of Balchem during the fourth quarter worth about $226,000. Finally, DekaBank Deutsche Girozentrale raised its position in shares of Balchem by 71.0% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 51,300 shares of the basic materials company’s stock valued at $7,662,000 after buying an additional 21,300 shares during the last quarter. 87.91% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Balchem

In other news, SVP Michael Robert Sestrick sold 1,929 shares of the stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $154.45, for a total value of $297,934.05. Following the completion of the transaction, the senior vice president now owns 4,878 shares in the company, valued at approximately $753,407.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Balchem news, Director David B. Fischer sold 5,000 shares of the company’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $152.98, for a total value of $764,900.00. Following the sale, the director now owns 9,009 shares of the company’s stock, valued at $1,378,196.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael Robert Sestrick sold 1,929 shares of Balchem stock in a transaction on Friday, May 10th. The stock was sold at an average price of $154.45, for a total value of $297,934.05. Following the transaction, the senior vice president now directly owns 4,878 shares of the company’s stock, valued at approximately $753,407.10. The disclosure for this sale can be found here. Company insiders own 1.25% of the company’s stock.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.